The HOPA Board identified two policy priorities which reflect the identity of our organization, help us work on behalf of our patients, serve our members’ interests, and create an action plan for best targeted impact. These priorities are explained in our health policy agenda. The board also identified eight issues of importance to monitor as they develop.
Ensure that biosimilar drugs reach the market but do not impact patient safety.
Describes the issue of counterfeit drugs and recommendations for legislative changes that aid in the prevention of counterfeit drug availability in the U.S. market.
Address the growing oncology drug shortages which prohibit patients from accessing or receiving the agents necessary for the treatment of cancer and cancer-related symptoms.
Policymakers and stakeholders should consider mitigation strategies to reduce IV therapy drug waste.
Support the hematology/oncology pharmacist as an essential component of patient care and recognize them as providers under Medicare Part B.
Improve access to oral chemotherapy for all patients; develop guidelines to promote safety in ordering, dispensing, and administering oral chemotherapy.
Ensure the responsible use of and access to pain medications for cancer patients.
Promote and improve patient safety by realizing the value and role that hematology/oncology pharmacists play in healthcare delivery.